rs529855742
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_000199.5(SGSH):โc.544C>Tโ(p.Arg182Cys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000062 in 1,613,150 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (โ โ ). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R182H) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000199.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
SGSH | NM_000199.5 | c.544C>T | p.Arg182Cys | missense_variant | 5/8 | ENST00000326317.11 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
SGSH | ENST00000326317.11 | c.544C>T | p.Arg182Cys | missense_variant | 5/8 | 1 | NM_000199.5 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152212Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000123 AC: 3AN: 244306Hom.: 0 AF XY: 0.0000150 AC XY: 2AN XY: 133022
GnomAD4 exome AF: 0.00000479 AC: 7AN: 1460820Hom.: 0 Cov.: 34 AF XY: 0.00000550 AC XY: 4AN XY: 726680
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152330Hom.: 0 Cov.: 33 AF XY: 0.00 AC XY: 0AN XY: 74486
ClinVar
Submissions by phenotype
Mucopolysaccharidosis, MPS-III-A Pathogenic:10
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Oct 06, 2021 | Variant summary: SGSH c.544C>T (p.Arg182Cys) results in a non-conservative amino acid change located in the Sulfatase, N-terminal domain (IPR000917) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.2e-05 in 244306 control chromosomes. c.544C>T has been reported in the literature in multiple individuals affected with Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome A) (example, Di Natale_1998, Valstar_2010, Heron_2011, Zanetti_2019). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in <10% of normal Sulfamidase enzyme activity in a homozygous patient (example, Zanetti_2019). Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 01, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Center for Medical Genetics, GenVams Trust | - | The Arg182Cys variant in SGSH has been reported in a hetoroallelic Italian patient. In the patient, the variant caused absence of restriction site of MspA11 enzyme. This cleaved the 296 bp segment to 200 and 96 bp segments. This study also noted the phenotype to be intermediate in terms of severity (di Natale et al, 1998). However, our patient, being homozygous for the Arg182Cs variant, showed intermediate-severe phenotype. The Arg182Cys variant has not been reported in the testing organization's (secondary organization here) internal database and has a minor allele frequency of 0.02% and 0.0008% in the 1000 genomes and ExAC databases respectively. The in silico prediction of the variant is probably damaging by PolyPhen-2 (HumDiv) and damaging by LRT, SIFT and MutationTaster2. - |
Pathogenic, criteria provided, single submitter | clinical testing | Genomic Research Center, Shahid Beheshti University of Medical Sciences | Dec 18, 2017 | - - |
Likely pathogenic, criteria provided, single submitter | literature only | Laboratory of Diagnosis and Therapy of Lysosomal Disorders, University of Padova | Jan 01, 2019 | PS3: Low in vitro enzymatic activity. PM2: Very low frequency in ExAc - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 27, 2022 | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 182 of the SGSH protein (p.Arg182Cys). This variant is present in population databases (rs529855742, gnomAD 0.006%). This missense change has been observed in individual(s) with mucopolysaccharidosis IIIA (PMID: 9554748, 21061399, 30809705). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 523015). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt SGSH protein function. Experimental studies have shown that this missense change affects SGSH function (PMID: 10727844). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tรผbingen | Nov 28, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Nov 11, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Rady Children's Institute for Genomic Medicine, Rady Children's Hospital San Diego | - | This variant has been previously reported as a compound heterozygous change in a patient with Mucopolysaccharidosis type IIIA (PMID: 21061399). In addition, another missense variant at this position, p.Arg182His, has been reported as a compound heterozygous change in a patient with Mucopolysaccharidosis type IIIA (PMID: 31718697). It is present in the heterozygous state in the gnomAD population database at a frequency of 0.001% (3/244306) and thus is presumed to be rare. The c.544C>T (p.Arg182Cys) variant affects a highly conserved amino acid and is predicted by multiple in silico tools to have a deleterious effect on protein function. Based on the available evidence, the c.544C>T (p.Arg182Cys) variant is classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Nov 07, 2021 | - - |
not provided Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 16, 2022 | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 21061399, 25807448, 9554748, 24816101) - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at